HK Stock Market Move | INNOVENT BIO (01801) rose over 3% intraday as seven innovative products, including XinerMei, were successfully included in the National Reimbursement Drug List.

date
10:24 17/11/2026
avatar
GMT Eight
INNOVENT BIO (01801) rose over 3% intraday. As of press time, it was up 1.79% at HK$85.4, with a turnover of HK$398 million.
INNOVENT BIO (01801) rose over 3% intraday, up 1.79% as of press time at HK$85.4, with a turnover of HK$398 million. On the news front, INNOVENT BIO recently announced that seven innovative products, including XinerMei and Xinmeiyue, were successfully included in the new version of the National Drug Catalog for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance (2026). The successful inclusion of the company's seven innovative drugs in the national reimbursement drug list covers disease areas with heavy social burden such as oncology (colorectal cancer, renal cancer, hematological tumors), cardiovascular and metabolic diseases, and autoimmune diseases. According to the announcement, products included in the national reimbursement drug list for the first time include XinerMei (mazdutide injection, GCG/GLP-1 dual receptor agonist), Xinmeiyue (picankibart injection, IL-23p19 inhibitor), DaboXin (ipilimumab N01 injection, CTLA-4 inhibitor), and Weifutai (quizartinib hydrochloride tablets, type II FLT3 inhibitor); products with newly added indications included in the catalog include DaboShu (sintilimab injection, anti-PD-1 monoclonal antibody) and Jiepali (pirtobrutinib tablets, non-covalent BTK inhibitor); Xinbile (tafolecimab injection, fully human PCSK9 monoclonal antibody) was successfully renewed. The new version of the national reimbursement drug list will be officially implemented starting January 1, 2027.